Plug Power: BMO Raises Price Target To $41 On Revised Guidance

On November 9th, Plug Power (NASDAQ: PLUG) reported its third quarter financial results. The company announced that it delivered 4,559 GenDrive units and had 16 hydrogen infrastructure systems operational for this quarter, which boosted revenues to $143.9 million for the period, up 15.5% quarter over quarter.

The company reported another quarter of negative gross margins as the cost of goods sold totaled $175 million this quarter, giving the company a negative $31.02 million gross profit. Because of this, the company reported net losses of $106.67 million, or an earning per share of negative $0.19. Additionally, the company raised full-year 2022 guidance to $900-$925 million.

A number of analysts raised their 12-month price targets on Plug Power after the results, bringing the 12-month average to US$46.59 or a 16% upside. Plug Power currently has 27 analysts covering the stock with 6 analysts having strong buy ratings, 14 have buy ratings and 7 have hold ratings on the stock. The street high sits at US$78 from H.C Wainwright while the lowest price target comes in at US$35.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

In BMO Capital Market’s third quarter review, they reiterate their market perform rating and raised their 12-month price target to $41 from $35 saying that the company is continuing its “Brisk Pace on Hydrogen Development.”

BMO is less focused on the company’s quarterly results and more focused on the company’s guidance and partnerships. They do highlight that the companies margins came in below their consensus, which they believe to reflect the challenges of sourcing hydrogen. Although they note, “we do not view this as a significant focus area for investors who remain focused on the ability of the company to become a leader in green hydrogen production and distribution.”

On the company updated 2022 guidance, they suspect that the company could further increase revenue guidance “as its confidence in electrolyzer sales is very strong.” They additionally believe that the company should have positive margins during the second half of 2022 going into 2023.

Lastly, the company expects to reduce its service costs on a per-unit basis by 30% over the next twelve months, BMO points out that the fuel business has been a drag on results/gross margins and they believe that this segment should be in “a decidedly different position 2H 2022 and 2023,” after its hydrogen production facilities come online.

Below you can see BMO’s updated 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Investors Are Returning To Mining Stocks | Rob McLeod – Cambria Gold Mines

How This Gold Stock Delivered a 32X Return | Martino De Ciccio – Montage Gold

America Can’t Stop Printing Money, What Happens to Gold? | Rod Husband – Epic Gold

Recommended

First Majestic Produces 3.4 Million Ounces of Silver in Q3 2026, Jerritt Canyon Restart Remains on Track

Altamira Gold Drills 134 Metres of 0.5 g/t Gold at Maria Bonita, Hole Ends in Mineralization

Related News

Trulieve Cannabis: Second Quarter 2021 Analyst Consensus Estimates

Trulieve Cannabis (CSE: TRUL) announced that they will be reporting their second quarter financials before...

Monday, August 9, 2021, 11:32:00 AM

Microsoft: Q3 Earnings Consensus Estimates

Microsoft (NASDAQ: MSFT) will be reporting their fiscal third quarter financials on April 27th after...

Monday, April 26, 2021, 04:02:00 PM

Harvest Health: Canaccord, Stifel Raise Price Targets

Earlier this week, Harvest Health & Recreation (CSE: HARV) released its third quarter results. The...

Thursday, November 12, 2020, 03:57:03 PM

Medmen: Canaccord Raises Price Target, Rating After Q4 Performance

On September 23, Medmen Enterprises (CSE: MMEN) reported their fiscal fourth-quarter financial results. The company...

Saturday, September 25, 2021, 01:05:00 PM

Canaccord Slashes Antibe Therapeutics Price Target A Month After Drug Trial Paused

On August 3, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Wednesday, September 29, 2021, 11:44:00 AM